Biologics Safety Testing

Biologics Safety Testing

Global Biologics Safety Testing Market to Reach US$12.9 Billion by 2030

The global market for Biologics Safety Testing estimated at US$5.9 Billion in the year 2023, is expected to reach US$12.9 Billion by 2030, growing at a CAGR of 11.8% over the analysis period 2023-2030. Biologics Safety Testing Services, one of the segments analyzed in the report, is expected to record a 12.1% CAGR and reach US$5.5 Billion by the end of the analysis period. Growth in the Biologics Safety Testing Kits & Reagents segment is estimated at 13.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 11.2% CAGR

The Biologics Safety Testing market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.2% and 9.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Biologics Safety Testing Market - Key Trends and Drivers Summarized

What Makes Biologics Safety Testing a Pillar of Biopharmaceutical Development?

Biologics safety testing stands as a fundamental pillar in the development of biopharmaceuticals, ensuring that complex biological products, including vaccines, monoclonal antibodies, gene therapies, and cell-based treatments, are safe for patient use. Unlike traditional chemical drugs, biologics are derived from living organisms, presenting unique challenges due to their intricate structures and potential to trigger immune responses. Safety testing involves a comprehensive array of assays aimed at detecting contaminants such as viruses, mycoplasma, and endotoxins that could compromise the product`s safety. Additionally, testing for host cell protein (HCP) contamination is crucial since residual proteins from production cell lines can provoke adverse immune reactions. The stringent nature of these tests is driven by the need to meet the high safety standards set by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The critical importance of biologics safety testing lies in its ability to safeguard public health and ensure that biologics are both safe and effective.

How Do Regulatory Requirements Influence Biologics Safety Testing?

Regulatory requirements are a driving force behind the evolution of biologics safety testing, dictating the methods and technologies used to ensure that biologic products meet stringent safety and quality standards. International bodies such as the FDA, EMA, and World Health Organization (WHO) have established comprehensive guidelines that specify the necessary safety tests, the frequency of these tests, and acceptable contamination thresholds. Compliance with these regulations is essential for companies aiming to bring biologics to market, as non-compliance can lead to significant delays, recalls, or outright rejection of a product. Over time, as biologics have become more complex, regulatory standards have become more rigorous, pushing the adoption of advanced testing techniques like next-generation sequencing (NGS) and mass spectrometry. These methods offer heightened sensitivity and specificity, capable of detecting even minute levels of contaminants. The constantly evolving regulatory landscape continues to drive innovation in biologics safety testing, ensuring that the industry remains equipped to address emerging safety challenges.

Which Technological Innovations Are Transforming Biologics Safety Testing?

Recent technological innovations are reshaping the field of biologics safety testing, leading to significant improvements in the accuracy, sensitivity, and efficiency of testing procedures. High-throughput screening (HTS) technologies represent one of the most impactful advancements, enabling the rapid testing of large sample volumes, thus accelerating the development timeline for biologics. Concurrently, the adoption of cell-based assays has gained momentum, providing more relevant physiological data compared to traditional in vitro methods. These assays are crucial for detecting potential immunogenicity and cytotoxicity early in the development process, offering deeper insights into the safety profile of biologics. Artificial intelligence (AI) and machine learning are also making their mark by enhancing data analysis capabilities, allowing for more precise identification of patterns and prediction of outcomes. Moreover, the advent of novel biosensors and microfluidic platforms has facilitated real-time, on-site testing, enabling continuous monitoring of biologics during production. These technological advancements are not only enhancing the reliability of safety testing but also streamlining workflows and reducing overall costs, making the biologics development process more efficient and effective.

What’s Driving the Rapid Growth in the Biologics Safety Testing Market?

The growth in the biologics safety testing market is driven by several factors. A primary driver is the rapid growth of the biologics sector itself, fueled by the increasing demand for cutting-edge therapies, including personalized medicine and immunotherapies. As the pipeline of biologics continues to expand, there is a heightened need for comprehensive safety testing, prompting biopharmaceutical companies to invest heavily in advanced testing technologies. Additionally, the rising prevalence of biosimilars—biologics that are highly similar to already approved products—has intensified the focus on safety testing to ensure these products meet equivalency and safety standards. Regulatory agencies have also played a significant role in this market growth by imposing more stringent safety testing requirements, necessitating more frequent and rigorous testing. The incorporation of automation, artificial intelligence, and next-generation sequencing into safety testing protocols has further propelled market expansion by enhancing efficiency and accuracy. Lastly, the globalization of the biopharmaceutical industry has led to increased efforts to harmonize safety standards across different regions, driving demand for standardized and reliable testing methods. These factors collectively are fueling the robust growth of the biologics safety testing market.

Select Competitors (Total 13 Featured) -
  • Avance Biosciences Inc.
  • Charles River Laboratories International, Inc.
  • Cytovance Biologics
  • Eurofins Scientific SE
  • Lonza Group AG
  • Merck KgaA
  • Pace Analytical Services, Inc.
  • Sartorius AG
  • SGS SA
  • Source BioScience PLC
  • Thermo Fisher Scientific, Inc.
  • Toxikon Corporation
  • WuXi AppTec
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Biologics Safety Testing – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Stringency in Regulatory Requirements Propels Market Growth for Biologics Safety Testing
Advancements in Analytical Technologies Strengthen the Business Case for Enhanced Safety Testing
Surging Demand for Biologics and Biosimilars Generates Accelerated Need for Comprehensive Safety Testing
Technological Innovations in Rapid Testing Methods Drive Adoption Across Biopharma Companies
Regulatory Compliance Standards Throw the Spotlight on the Critical Importance of Safety Testing in Biologics Development
Expanding Biologics Pipeline Spurs Growth in the Safety Testing Market
Rising Incidence of Biologic Contamination Issues Sustains Demand for Rigorous Testing Protocols
Increasing Focus on Patient Safety and Product Quality Drives Adoption of Advanced Biologics Safety Testing Solutions
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Biologics Safety Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Biologics Safety Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Biologics Safety Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Biologics Safety Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Monoclonal Antibody Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Monoclonal Antibody Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Monoclonal Antibody Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Vaccine Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Vaccine Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Vaccine Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Blood & Blood Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Blood & Blood Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Blood & Blood Product Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Cellular & Gene Therapy Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Cellular & Gene Therapy Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Cellular & Gene Therapy Product Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Mycoplasma Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Mycoplasma Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for Mycoplasma Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Sterility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for Sterility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: World 16-Year Perspective for Sterility Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Endotoxin Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 39: World Historic Review for Endotoxin Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: World 16-Year Perspective for Endotoxin Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 42: World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: World 16-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 44: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: USA Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: USA 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: USA Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: USA 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: USA Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: USA 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
CANADA
TABLE 53: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Canada 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Canada 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Canada 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
JAPAN
Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 62: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Japan 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 65: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Japan 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Japan 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
CHINA
Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 71: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: China Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: China 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 74: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: China Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: China 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 77: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: China Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: China 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
EUROPE
Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 80: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Biologics Safety Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for Biologics Safety Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Europe 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Europe 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Europe 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
FRANCE
Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 92: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: France Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: France 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 95: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: France Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: France 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 98: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: France Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: France 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
GERMANY
Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 101: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Germany 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 104: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Germany 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 107: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Germany 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
ITALY
TABLE 110: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Italy 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 113: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Italy 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 116: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Italy 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
UNITED KINGDOM
Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 119: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: UK Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: UK 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 122: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: UK Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: UK 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 125: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: UK Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: UK 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Europe Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Europe 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Europe Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Europe 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Europe 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Asia-Pacific Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Asia-Pacific 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Asia-Pacific Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Asia-Pacific 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Asia-Pacific 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 146: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Rest of World Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Rest of World 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
TABLE 149: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Rest of World Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Rest of World 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2024 & 2030
TABLE 152: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Rest of World Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Rest of World 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings